Co-Authors
This is a "connection" page, showing publications co-authored by Thomas Hensing and Clarissa Parker.
Connection Strength
2.540
-
Clinical evaluation and staging of patients who have lung cancer. Hematol Oncol Clin North Am. 2005 Apr; 19(2):219-35, v.
Score: 0.267
-
A personalized treatment for lung cancer: molecular pathways, targeted therapies, and genomic characterization. Adv Exp Med Biol. 2014; 799:85-117.
Score: 0.245
-
Molecular biomarkers for future screening of lung cancer. J Surg Oncol. 2013 Oct; 108(5):327-33.
Score: 0.238
-
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer. Anticancer Drugs. 2006 Jul; 17(6):697-704.
Score: 0.146
-
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005 Feb; 47(2):253-9.
Score: 0.132
-
Duration of therapy in advanced, metastatic non-small-cell lung cancer. Clin Adv Hematol Oncol. 2003 Jan; 1(1):33-8.
Score: 0.114
-
Brain metastases. Curr Treat Options Oncol. 2001 Dec; 2(6):537-47.
Score: 0.106
-
The role of induction therapy in the management of resectable non-small cell lung cancer. Cancer Control. 2000 Jan-Feb; 7(1):45-55.
Score: 0.093
-
Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer. Curr Opin Pulm Med. 1999 Jul; 5(4):194-200.
Score: 0.090
-
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9.
Score: 0.089
-
Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):51-8.
Score: 0.081
-
Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014 Mar 30; 5(6):1392-433.
Score: 0.062
-
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel. Cancer. 2003 Aug 15; 98(4):779-88.
Score: 0.060
-
Personalized treatment of lung cancer. Semin Oncol. 2011 Apr; 38(2):274-83.
Score: 0.051
-
Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database. J Clin Bioinforma. 2011 Feb 28; 1(8):1-11.
Score: 0.050
-
Mind-mapping for lung cancer: towards a personalized therapeutics approach. Adv Ther. 2011 Mar; 28(3):173-94.
Score: 0.050
-
Generation of comprehensive thoracic oncology database--tool for translational research. J Vis Exp. 2011 Jan 22; (47).
Score: 0.050
-
Nanocytology for field carcinogenesis detection: novel paradigm for lung cancer risk stratification. Future Oncol. 2011 Jan; 7(1):1-3.
Score: 0.050
-
A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer. Cancer Invest. 2010 Feb; 28(2):208-15.
Score: 0.047
-
Prevalence of poor performance status in lung cancer patients: implications for research. J Thorac Oncol. 2008 Feb; 3(2):125-9.
Score: 0.041
-
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):145-51.
Score: 0.041
-
An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol. 2007 Sep; 5(8):381-7.
Score: 0.039
-
Should health-related quality of life be measured in cancer symptom management clinical trials? Lessons learned using the functional assessment of cancer therapy. J Natl Cancer Inst Monogr. 2007; (37):53-60.
Score: 0.038
-
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 2006 Sep; 53(3):331-7.
Score: 0.036
-
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):218-25.
Score: 0.036
-
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. Lung Cancer. 2005 Mar; 47(3):413-9.
Score: 0.033
-
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. J Clin Oncol. 2004 Nov 01; 22(21):4341-50.
Score: 0.032
-
Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). Ann Surg Oncol. 2004 Oct; 11(10):900-6.
Score: 0.032
-
Clinical applications of proton MR spectroscopy in oncology. Technol Cancer Res Treat. 2002 Feb; 1(1):17-28.
Score: 0.027
-
Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25.
Score: 0.026
-
Optical detection of buccal epithelial nanoarchitectural alterations in patients harboring lung cancer: implications for screening. Cancer Res. 2010 Oct 15; 70(20):7748-54.
Score: 0.024
-
Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53.
Score: 0.023
-
Nanoscale cellular changes in field carcinogenesis detected by partial wave spectroscopy. Cancer Res. 2009 Jul 01; 69(13):5357-63.
Score: 0.022
-
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol. 2007 Sep; 2(9):845-53.
Score: 0.020
-
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story. J Thorac Oncol. 2006 Jan; 1(1):52-60.
Score: 0.018
-
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol. 2006 Jan; 17(1):104-9.
Score: 0.017
-
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004 Dec 01; 22(23):4837-45.
Score: 0.016